Carelon has updated its outpatient clinical appropriateness guidelines to include whole-exome sequencing (WES) and whole-genome sequencing (WGS) for defined outpatient scenarios. The change, effective last week, signals improved payor coverage for comprehensive genomic testing across multiple health plans and may raise downstream demand for clinical laboratories offering WES/WGS. The guidelines specify medically necessary conditions in both prenatal and postnatal settings, including indications such as abnormal fetal findings after prior testing, and postnatal presentations with multiple anomalies before age one or certain early-onset epilepsy/developmental delay presentations. Carelon also limits WGS as not medically necessary in prenatal outpatient contexts. For lab providers such as GeneDx, the update represents a coverage milestone tied to clinical actionability and quality standards (CLIA certification plus CAP accreditation). (Article references: Carelon guideline update reporting.)